Sharekhan recommended Hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7931 in its research report dated May 13, 2019.
Sharekhan's research report on GlaxoSmithKline Consumer Healthcare
In Q4FY2019, GlaxoSmithKline Consumer Healthcare (GSK Consumer) recorded a strong operating performance with steady volume growth of 6.3% (revenue growth of 9% y-o-y) and OPM expanding by 357BPS to 24.8%. The flagship brand, Horlicks maintained its leadership position with 43% market share in the HFD category; Variants such as Protein+ and Growth+ are gaining good acceptance in the domestic market. Volume growth is likely to sustain at 5-7%; Margins are likely to come under pressure due to spike in input prices.
Prudent for shareholders to hold the stock as the share-swap deal is more favourable towards shareholders of GSK Consumer; we maintain Hold with an unchanged PT of Rs. 7,931.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.